If you sold your Mesoblast Limited (ASX: MSB) shares yesterday, you’d likely be kicking yourself today.
Yesterday, Mesoblast Limited shares finally emerged from their multi-day trading halt to be heavily sold down by the market.
Though headline figures showed a modest 18% fall between open and close (i.e. during trading hours), comparing yesterday’s close price to the prior day’s close price shows an enormous 42% fall.
However, if you sold a large stake during yesterday’s selling frenzy, you may today be kicking yourself because Mesoblast Limited shares climbed as much as 18% higher today.
What’s going on?
A week ago, more than 5% of Mesoblast shares were held short, meaning investors were betting on a decline in the biotechnology company’s share price. As a result of yesterday’s huge falls those ‘short sellers’ would likely have made significant profits and many would have closed out their short positions by buying back the company’s shares. However, that likely doesn’t explain today’s share price rally.
Another plausible explanation could come from analyst rating changes. According to Dow Jones Newswires, Bell Potter analysts reduced their Mesoblast price target 27% to $3.39. However, Macquarie’s price target stands at $0.81 cents.
When (not if) you find yourself in the position of holding shares in a company that is suffering a massive intraday share price fall, it is hard to act rationally. However, by following a simple trading rule, such as ‘Don’t sell a share when it falls by more than 5% in a single day’, you may actually save yourself some money and heartache. It doesn’t always work, sure, but at the very least it’ll prompt you to scrutinise the timing of your sell decision.
If you are inclined to think Mesoblast will come under more selling pressure, today could be an opportunity to sell out.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...
Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
Returns as of 6th October 2020
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- ALL ORDINARIES finishes higher Monday: 10 shares you missed – October 30, 2017 4:44pm
- Are these the secrets behind Australia’s best ASX investors? – October 30, 2017 3:43pm
- My Aussie Share Market Investing Do’s of 2017/2018 – October 30, 2017 1:13pm